Godfrey Keith M, Cutfield Wayne, Chan Shiao-Yng, Baker Philip N, Chong Yap-Seng
NIHR Southampton Biomedical Research Centre, University Hospital Southampton, NHS Foundation Trust, Southampton, UK.
MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Mailpoint 95, Southampton, SO16 6YD, UK.
Trials. 2017 Mar 20;18(1):131. doi: 10.1186/s13063-017-1875-x.
Improved maternal nutrition and glycaemic control before and during pregnancy are thought to benefit the health of the mother, with consequent benefits for infant body composition and later obesity risk. Maternal insulin resistance and glycaemia around conception and in early pregnancy may be key determinants of maternal physiology and placental function, affecting fetal nutrient supply and maternal-feto-placental communications throughout gestation, with implications for later postnatal health.
METHODS/DESIGN: This double-blind randomised controlled trial will recruit up to 1800 women, aged 18-38 years, who are planning a pregnancy in the United Kingdom (UK), Singapore and New Zealand, with a view to studying 600 pregnancies. The primary outcome is maternal glucose tolerance at 28 weeks' gestation following an oral glucose tolerance test. Secondary outcomes include metabolic, molecular and health-related outcomes in the mother and offspring, notably infant body composition. Participants will be randomly allocated to receive a twice-daily control nutritional drink, enriched with standard micronutrients, or a twice-daily intervention nutritional drink enriched with additional micronutrients, myo-inositol and probiotics, both demonstrated previously to assist in maintaining healthy glucose metabolism during pregnancy. Myo-inositol is a nutrient that enhances cellular glucose uptake. The additional micronutrients seek to address deficiencies of some B-group vitamins and vitamin D that are both common during pregnancy and that have been associated with maternal dysglycaemia, epigenetic changes and greater offspring adiposity. Women who conceive within a year of starting the nutritional drinks will be followed through pregnancy and studied with their infants at six time points during the first year of life. Blood, urine/stool, hair and cheek swabs will be collected from the mothers for genetic, epigenetic, hormone, nutrient and metabolite measurements, and assessments of the mother's body composition, anthropometry, health, diet and lifestyle will be made. Infants will also undergo hair, cheek swab, urine and stool sampling for similar biological measurements; infant body composition will be assessed and feeding recorded.
There is an increasing focus on the need to optimise maternal nutrition starting prior to conception. This trial will provide evidence on the potential for nutritional interventions beginning prior to conception to promote healthy maternal and offspring outcomes.
ClinicalTrials.gov, identifier: NCT02509988 , Universal Trial Number U1111-1171-8056. Registered on 16 July 2015. This is an academic-led study by the EpiGen Global Research Consortium.
孕期前后改善孕产妇营养和血糖控制被认为有益于母亲健康,进而对婴儿身体组成及日后肥胖风险产生有益影响。受孕前后及孕早期的母体胰岛素抵抗和血糖水平可能是母体生理和胎盘功能的关键决定因素,影响整个孕期胎儿的营养供应以及母胎-胎盘间的交流,对日后的产后健康具有重要意义。
方法/设计:这项双盲随机对照试验将招募多达1800名年龄在18至38岁之间、计划在英国、新加坡和新西兰怀孕的女性,旨在研究600例妊娠情况。主要结局指标为口服葡萄糖耐量试验后孕28周时的母体葡萄糖耐量。次要结局指标包括母亲和后代的代谢、分子及健康相关结局,尤其是婴儿身体组成。参与者将被随机分配,分别接受每日两次的对照营养饮料(富含标准微量营养素)或每日两次的干预营养饮料(富含额外的微量营养素、肌醇和益生菌,此前已证明这两种饮料有助于维持孕期健康的葡萄糖代谢)。肌醇是一种能增强细胞对葡萄糖摄取能力的营养素。额外的微量营养素旨在解决孕期常见的一些B族维生素和维生素D缺乏问题,这些营养素缺乏与母体血糖异常、表观遗传变化及后代肥胖增加有关。在开始饮用营养饮料后一年内受孕的女性,将在孕期接受跟踪,并在其婴儿出生后第一年的六个时间点进行研究。将采集母亲的血液、尿液/粪便、毛发和颊拭子样本,用于进行基因、表观遗传、激素、营养素和代谢物测量,并对母亲的身体组成、人体测量、健康状况、饮食和生活方式进行评估。婴儿也将接受毛发、颊拭子、尿液和粪便采样,用于类似的生物学测量;将评估婴儿的身体组成并记录喂养情况。
越来越多的人关注在受孕前就优化孕产妇营养的必要性。本试验将为受孕前开始的营养干预对促进母亲和后代健康结局的潜力提供证据。
ClinicalTrials.gov标识符:NCT02509988,通用试验编号U1111-1171-8056。于2015年7月16日注册。这是一项由EpiGen全球研究联盟主导的学术研究。